BMRN

AI Memo

BioMarin Pharmaceutical

As of 2026-09-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 beat and raised FY26 guidance • 2026-08-06

Base target: $73 / p=50% prob

Biggest risk

The recent earnings catalyst appears substantially priced in, while the larger upside depends on regulatory progress, clinical-data reception, and successful Amicus integration. Delays or weaker commercial uptake could pressure the shares.

Invalidation

Break below $54 or thesis failure.

What would change my mind?

The Q2 revenue beat, raised FY26 guidance, strong VOXZOGO demand, and potential hypochondroplasia expansion provide a credible positive setup. Amicus integration could broaden growth and improve profitability if execution is strong [#SEC-8K-2026-08-06].

Research note

Recommendation

—

Confidence

medium

As of

2026-09-02

Base target

$73

p=50%

Bull target

$86

p=25%

Bear target

$54

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Amicus portfolio integration and synergy realization
The Q2 revenue beat, raised FY26 guidance, strong VOXZOGO demand, and potential hypochondroplasia expansion provide a credible positive setup.
Amicus integration could broaden growth and improve profitability if execution is strong [#SEC-8K-2026-08-06].

BearKey bullets

Clinical-data or regulatory-execution risk around the hypochondroplasia program.
FDA review, timing, or approval risk for the VOXZOGO hypochondroplasia sNDA.
High expectations after the Q2 beat and guidance raise could increase downside from any demand, margin, or guidance disappointment.

WatchKey bullets

Q2 2026 beat and raised FY26 guidance

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $73 (p=50%)

Target spread vs base: +18% / -26%

Scenario probabilities

Bull Target: $86 (p=25%)Base Target: $73 (p=50%)Bear Target: $54 (p=25%)

Commentary

News tone is constructive after the Q2 beat, raised guidance, and portfolio expansion. The SEC earnings release provides strong primary-source support [#SEC-8K-2026-08-06]; a stored secondary recap also reports a $989.7 million quarter and positive share reaction [#PR-EARNINGS-2026-08-20]. Social, options, short-interest, and employee-sentiment data are unavailable; zero placeholders should not be interpreted as positive signals. The setup supports cautious monitoring rather than a high-conviction upgrade.

As of 2026-09-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Amicus portfolio integration and synergy realization

Scenarios

Bull Target (Scenario probability)

$86 / p=25% prob

Base Target (Scenario probability)

$73 / p=50% prob

Bear Target (Scenario probability)

$54 / p=25% prob

Analysis 2026-09-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.60

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-06
Q2 2026 beat and raised FY26 guidance
BioMarin reported Q2 revenue of approximately $990 million, up 20% year over year, and increased full-year 2026 revenue, VOXZOGO revenue, and non-GAAP EPS guidance [#SEC-8K-2026-08-06]. The catalyst is supportive but largely reflected in the post-earnings move.
Prob 85.00% • Move 4.00% • Priced-in 85.00%
EVENT2026-09-30
VOXZOGO hypochondroplasia regulatory and data milestones
BioMarin submitted an sNDA for VOXZOGO in hypochondroplasia following positive Phase 3 CANOPY-HCH-3 results. The full dataset is expected at a September medical meeting, with an application-status update planned alongside Q3 earnings [#SEC-8K-2026-08-06].
Prob 70.00% • Move 8.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Amicus portfolio integration and synergy realization
2027-12-31
Integration of GALAFOLD and POMBILITI plus OPFOLDA expands BioMarin’s commercial portfolio. Management expects the combination and cost synergies to support revenue growth, margin expansion, and operating cash flow through the mid-2030s [#SEC-8K-2026-08-06].
Prob 65% • Move 12% • Priced-in 50%

Risks

Clinical-data or regulatory-execution risk around the hypochondroplasia program.
FDA review, timing, or approval risk for the VOXZOGO hypochondroplasia sNDA.
High expectations after the Q2 beat and guidance raise could increase downside from any demand, margin, or guidance disappointment.
Integration, cost-synergy, and commercial execution risk following the Amicus portfolio addition.

Peers

Symbol	Summary
CORT	Similarly sized specialty biopharma with commercial products and pipeline exposure; a loose operating and valuation comparison rather than a direct rare-disease peer.
EXEL	Same-sector commercial biopharma with an established product base; useful for broader execution comparison but not a close portfolio match.
AMGN	Large commercial biotechnology peer with greater scale and diversification; relevant for sector context but materially less comparable in size and growth profile.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-02

Loading AI feed…

Symbol

Summary

CORT

Similarly sized specialty biopharma with commercial products and pipeline exposure; a loose operating and valuation comparison rather than a direct rare-disease peer.

EXEL

Same-sector commercial biopharma with an established product base; useful for broader execution comparison but not a close portfolio match.

AMGN

Large commercial biotechnology peer with greater scale and diversification; relevant for sector context but materially less comparable in size and growth profile.